Local reactions included pain at injection site, redness and swelling and were recorded by the participant's parents/legal guardians in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (>) 0.0 to 2.0 cm; moderate: >2.0 to 7.0 cm; and severe: >7.0 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Exact 2-sided confidence interval (CI) was based on the Clopper and Pearson method.

Dose 2 safety population included participants who received the first and second dose of investigational product at Visit 1 and Visit 3 and for whom safety information was available from Visit 3. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Systemic events included fever, decreased appetite, increased sleep and irritability and were recorded by the participant's parents/legal guardians in an e-diary. Fever was defined as temperature greater than or equal to (>=) 38.0 degrees (deg) Celsius (C), categorized as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C; decreased appetite graded as mild: decreased interest in eating, moderate: decreased oral intake and severe: refusal to feed; increased sleep graded as mild: increased or prolonged sleeping bouts, moderate: slightly subdued, interfered with daily activity and severe: disabling, not interested in usual daily activity; irritability graded as mild: easily consolable, moderate: required increased attention and severe: inconsolable, crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.

Dose 2 safety population included participants who received the first and second dose of investigational product at Visit 1 and Visit 3 and for whom safety information was available from Visit 3. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

The use of antipyretic medication was recorded by the participant's parents/legal guardians in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 2 safety population included participants who received the first and second dose of investigational product at Visit 1 and Visit 3 and for whom safety information was available from Visit 3. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Dose 2 safety population included participants who received the first and second dose of investigational product at Visit 1 and Visit 3 and for whom safety information was available from Visit 3. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 2 safety population included participants who received the first and second dose of investigational product at Visit 1 and Visit 3 and for whom safety information was available from Visit 3. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 2 safety population included participants who received the first and second dose of investigational product at Visit 1 and Visit 3 and for whom safety information was available from Visit 3. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Immediate AEs were defined as AEs occurring within the first 30 minutes after administration of the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 2 safety population included participants who received the first and second dose of investigational product at Visit 1 and Visit 3 and for whom safety information was available from Visit 3. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Percentage of participants achieving rSBA titer >=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline in participants who received vaccinations 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. Analysis was performed on Post Dose (PD) 2 Evaluable Immunogenicity Population (EIP) (PD2 EIP).

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

Percentage of participants achieving rSBA titer >=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at 1 month after vaccination 1 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

Percentage of participants achieving rSBA titer >=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

Percentage of participants achieving rSBA titer >=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at 1 month after vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).

PD2 EIP: participants enrolled and eligible through 1 month after vaccination 2; received vaccine at visit (V) 1 and V3; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and at 1 month after dose 2 (V4: window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, and MenY assay result at V4, received no prohibited vaccines/treatment and had no protocol deviations through V4. Here, N =participants evaluable for this outcome measure.

Local reactions included pain at injection site, redness and swelling and were recorded by the participant's parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: >0.0 to 2.0 cm; moderate: >2.0 to 7.0 cm; and severe: >7.0 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 1 safety population included participants who received the first dose of investigational product at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3.

Systemic events included fever, decreased appetite, increased sleep and irritability and were recorded in e-diary. Fever was defined as temperature >=38.0 deg C, categorized as >=38.0 to 38.4 deg C, >38.4 to 38.9 deg C,>38.9 to 40.0 deg C and >40.0 deg C; decreased appetite graded as mild: decreased interest in eating, moderate: decreased oral intake and severe: refusal to feed; increased sleep graded as mild: increased or prolonged sleeping bouts, moderate: slightly subdued, interfered with daily activity and severe: disabling, not interested in usual daily activity; irritability graded as mild: easily consolable, moderate: required increased attention and severe: inconsolable, crying could not be comforted. Exact 2-sided CI was based on Clopper and Pearson method.

Dose 1 safety population included participants who received the first dose of investigational product at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3.

The use of antipyretic medication was recorded by the participant's parents/legal guardians in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 1 safety population included participants who received the first dose of investigational product at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3.

An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Dose 1 safety population included participants who received the first dose of investigational product at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3.

An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 1 safety population included participants who received the first dose of investigational product at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3.

Immediate AEs were defined as AEs occurring within the first 30 minutes after administration of the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method.

Dose 1 safety population included participants who received the first dose of investigational product at Visit 1 and for whom safety information was available from Visit 1 to prior to Visit 3.

Percentage of participants achieving rSBA titer >=1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after Vaccination 1 in participants who received Vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented. Analysis was performed on post-dose 1 (PD1) evaluable immunogenicity population (EIP).

PD1 EIP: participants enrolled and eligible through V2; received vaccine at V1; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and Month 1 (V2; 1 month after dose 1: window 28-42 days); had at least 1 valid, determinate MenA, MenC, MenW-135 and MenY assay result at V2, received no prohibited vaccines/treatment and had no protocol deviations through V2. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Percentage of participants achieving rSBA titer >= 1:128 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after vaccination 1 in participants who received vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD1 EIP: participants enrolled and eligible through V2; received vaccine at V1; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and Month 1 (V2; 1 month after dose 1: window 28-42 days); had at least 1 valid, determinate MenA, MenC, MenW-135 and MenY assay result at V2, received no prohibited vaccines/treatment and had no protocol deviations through V2. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the rSBA titers (based on the Student t distribution).

PD1 EIP: participants enrolled and eligible through V2; received vaccine at V1; blood drawn for assay testing within time frames at Month 0 (V1; before dose 1) and Month 1 (V2; 1 month after dose 1: window 28-42 days); had at least 1 valid, determinate MenA, MenC, MenW-135 and MenY assay result at V2, received no prohibited vaccines/treatment and had no protocol deviations through V2. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Percentage of participants achieving hSBA titers >= 1:4 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after vaccination 1 in participants who received Vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD1 EIP:participants enrolled & eligible through V2;received vaccine at V1;blood drawn for assay testing within time frames at Month 0 (V1; before dose1) & Month1 (V2;1 month after dose1:window 28-42 days); had at least 1 valid, determinate MenA, MenC, MenW-135 & MenY assay result at V2, received no prohibited vaccines/treatment & had no protocol deviation through V2.N=signifies participants evaluable for this outcome measure.'Number Analyzed' signifies participants evaluable for specified row

Percentage of participants achieving hSBA titers >= 1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline and 1 month after vaccination 1 in participants who received Vaccination 1 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD1 EIP:participants enrolled & eligible through V2;received vaccine at V1;blood drawn for assay testing within time frames at Month 0 (V1; before dose1) & Month1 (V2;1 month after dose1:window 28-42 days); had at least 1 valid, determinate MenA, MenC, MenW-135 & MenY assay result at V2, received no prohibited vaccines/treatment & had no protocol deviation through V2.N=signifies participants evaluable for this outcome measure.'Number Analyzed' signifies participants evaluable for specified row

GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the hSBA titers (based on the Student t distribution).

PD1 EIP:participants enrolled & eligible through V2;received vaccine at V1;blood drawn for assay testing within time frames at Month 0 (V1; before dose1) & Month1 (V2;1 month after dose1:window 28-42 days); had at least 1 valid, determinate MenA, MenC, MenW-135 & MenY assay result at V2, received no prohibited vaccines/treatment & had no protocol deviation through V2.N=signifies participants evaluable for this outcome measure.'Number Analyzed' signifies participants evaluable for specified row.

Percentage of participants achieving hSBA titers >= 1:4 for each serogroup MenA, MenC, MenW-135 and MenY at baseline, 1 month after vaccination 1, at vaccination 2 and 1 month after vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD2 EIP:participant enrolled & eligible through 1month after vaccination2;received vaccine at V1 &V3;blood drawn for assay testing within time frame at Month0 (V1;before dose1) & at 1 month after dose2 (V4:window 28-42 days); at least 1 valid, determinate MenA, MenC, MenW-135, & MenY assay result at V4, received no prohibited vaccine/treatment & had no protocol deviation through V4.Here,N=participant evaluable for outcome measure.'Number Analyzed' signify participant evaluable for specified row

Percentage of participants achieving hSBA titers >= 1:8 for each serogroup MenA, MenC, MenW-135 and MenY at baseline, 1 month after vaccination 1, at vaccination 2 and 1 month after vaccination 2 in participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD2 EIP:participant enrolled & eligible through 1month after vaccination2;received vaccine at visit 1,3;blood drawn for assay testing within time frames at Month0 (V1;before dose1) & at 1month after dose2(V4:window 28-42 days);at least 1 valid,determinate MenA, MenC,MenW-135, & MenY assay result at V4,received no prohibited vaccine/treatment & had no protocol deviation through V4.Here,N=participant evaluable for outcome measure. 'Number Analyzed' signify participant evaluable for specified row.

GMT was derived by calculating the mean on the natural log scale based on the t-distribution, then exponentiating the results. CIs were obtained by exponentiating the limits of CIs for the mean logarithm of the hSBA titers (based on the Student t distribution).

PD2 EIP:participants enrolled & eligible through 1 month after vaccination2; received vaccine at visit (V) 1 & V3;blood drawn for assay testing within time frames at Month0 (V1; before dose 1) & at 1 month after dose2 (V4: window 28-42 days);at least 1 valid,determinate MenA, MenC, MenW-135, & MenY assay result at V4,received no prohibited vaccines/treatment & had no protocol deviation through V4.Here,N=participants evaluable for this outcome measure & n=participant evaluable for specified row.

Percentage of participants achieving rSBA Titers >= 1:128 for each serogroup MenA, MenC, MenW-135 and MenY at baseline, 1 month after vaccination 1, at vaccination 2 and 1 month after vaccination 2 in Participants who received vaccination 1 and 2 were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.

PD2 EIP:participants enrolled & eligible through 1 month after vaccination2; received vaccine at visit (V) 1 & V3;blood drawn for assay testing within time frames at Month0 (V1; before dose 1) & at 1 month after dose2 (V4: window 28-42 days);at least 1 valid,determinate MenA, MenC, MenW-135, & MenY assay result at V4,received no prohibited vaccines/treatment & had no protocol deviation through V4.Here,N=participants evaluable for this outcome measure & n=participant evaluable for specified row